my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
09-07-2005: Chiron Corporation issued the following statement from Chiron's independent board directors in response to the offer from Novartis AG on September 1, 2005, to acquire the approximately 58% of Chiron shares that Novartis does not already own for $40 per Chiron share in cash:
"Over the 10 years since Novartis has been Chiron's largest stockholder, Chiron has regularly discussed with Novartis a number of strategic initiatives, including mergers, significant acquisitions and other transactions, including transactions initiated by Novartis. As a result, Chiron has had an on-going dialogue with Novartis regarding its intentions with respect to its investment in Chiron. Chiron's independent directors have not, however, solicited an offer to buy Chiron.
"We are pleased by the fact that Novartis continues to recognize Chiron's promising prospects, as do Chiron's independent directors.
"After thorough analysis and consideration of Novartis' offer to acquire the shares of Chiron it does not already own for $40.00 per share in cash, the independent directors of Chiron have determined that this offer is inadequate."
Watchlist
This is where you can add this news to your personal favourites
Orion sues Sun Pharmaceuticals in the U.S. to enforce a patent for Stalevo
Orion Corporation has filed a patent infringement lawsuit in the United States to enforce its formulation patent, U.S. Patent No. 6,500,867, against Sun Pharmaceutical Industries Inc. and Sun Pharmaceutical Industries Limited, who seek to market generic versions of Stalevo® tablets (25/100/ ... more
Novartis completes agreement with Bayer Schering related to Betaseron rights and manufacturing
Novartis has completed an agreement with Bayer Schering Pharma AG (Bayer Schering) related to various rights for the multiple sclerosis treatment Betaseron® (interferon beta-1b) and has received a one-time payment of approximately USD 200 million. As part of the transaction, which was anno ... more
Bayer completes acquisition of U.S. biologics manufacturing facility from Novartis
Bayer Schering Pharma AG, Germany, has completed the acquisition of a biologics manufacturing facility in Emeryville, California from Novartis. Bayer will manufacture its multiple sclerosis drug Betaseron® at the Emeryville site, retain full control of all manufacturing and process technolo ... more
Novartis completes agreement with Bayer Schering related to Betaseron rights and manufacturing
Novartis has completed an agreement with Bayer Schering Pharma AG (Bayer Schering) related to various rights for the multiple sclerosis treatment Betaseron® (interferon beta-1b) and has received a one-time payment of approximately USD 200 million. As part of the transaction, which was anno ... more
Chiron Delivers FLUVIRIN(R) Influenza Virus Vaccine to U.S. Customer
Chiron Corporation announced that it has initiated the first delivery and release of FLUVIRIN(R) influenza virus vaccine to customers in the United States for the 2005-2006 influenza season. The company expects to continue to deliver shipments of FLUVIRIN vaccine throughout October and Nove ... more
Chiron Responds to Novartis Offer
Chiron Corporation issued the following statement from Chiron's independent board directors in response to the offer from Novartis AG on September 1, 2005, to acquire the approximately 58% of Chiron shares that Novartis does not already own for $40 per Chiron share in cash: "Over the 10 ye ... more
Chiron is a 20 year old company with main office in the lovely city of Trondheim in the northern country of Norway. Our staff is comprised of 17 talented people with backgrounds in Chemistry, Biochemistry and Economics. Gruppebilde-ChironSince 1983 we have supplied reference standards of ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2011 CHEMIE.DE Information Service GmbH, All rights reserved
